Motesanib ≥98%|CAS:453562-69-1|5 mg|10 mg|25 mg

|Motesanib is an inhibitor of VEGFR 1/2/3, PDGFR, c-Kit, and RET that displays anticancer chemotherapeutic and anti-angiogenic activities. In vivo, motesanib inhibits tumor growth of xenografts of various cancers. Motesanib is currently in clinical trials as a potential treatment for non-small cell lung cancer (NSCLC), breast cancer, and medullary thyroid cancer.|C22H23N5O|373.45||Ambient|